Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Nokian Tyres to change stock symbol to TYRES effective May 20, 2019

Nokian Tyres plc Stock Exchange Release May 16, 2019 9:00 a.m. Nokian Tyres plc will change its trading code (stock symbol) on Nasdaq Helsinki to TYRES, effective at the start of trading on Monday, May 20, 2019. The current trading code for Nokian Tyres is NRE1V.  Share details as of May 20, 2019:Company name: Nokian Tyres plcNew trading code: TYRESISIN: FI0009005318 Nokian Tyres plcPäivi AntolaSVP, Corporate Communications and Investor RelationsTel. +358 10 401 7327 Distribution: Nasdaq Helsinki Oy, media and www.nokiantyres.com

Terveystalo's network of occupational health services to expand: Terveystalo acquires Etelä-Karjalan Työkunto Oy

Press Release 16 May 2019 Terveystalo will buy the operations of Etelä-Karjalan Työkunto Oy by an agreement signed on 15 May 2019. The old customer relationship remains unchanged. Etelä-Karjalan Työkunto Oy is the largest company providing comprehensive occupational health services in its region. Työkunto Oy offers versatile occupational health services for South Karelia's Social and Health Services (Eksote), Lappeenranta City and other owners of Eksote. In addition, the company provides occupational health services for businesses, entrepreneurs and farmers. The company employs 58

MSAB: Annual General Meeting Notice 2019

The Annual General Meeting in MSAB on 15 May 2019 decided to: · Adopt the income statement and the balance sheets as presented in the Annual Report, and to discharge from liability the Board of Directors and the Chief Executive Officer. · Adopt the Board’s proposal to distribute a dividend of SEK 2.20 per share. MSAB B will trade ex-dividend as of 16 May 2019. The dividend payment date is set to 22 May 2019. · Re-elect Henrik Tjernberg as Chairman of the Board, re-elect Jan-Olof Backman and Carl Bildt and new elect Ann Hellenius och Linda Nyberg as ordinary Board members. ·

Consortium led by EQT and ADIA enters exclusive negotiations to acquire skincare company Nestlé Skin Health

· EQT and a wholly owned subsidiary of the Abu Dhabi Investment Authority (“ADIA”) have partnered with a wholly owned subsidiary of the Public Sector Pension Investment Board (“PSP Investments”) and other renowned institutional investors · The consortium has entered into exclusive negotiations to acquire Nestlé Skin Health, a leading global skincare company · The new owners plan to support Nestlé Skin Health in its next period of growth and innovation by leveraging EQT’s strong healthcare expertise, local angles and industrial network A consortium comprising EQT VIII fund (“EQT”

Saga Tankers ASA : Q1 2019 financial results

(Oslo, 15 May 2019) Saga Tankers ASA ("Saga", OSE: SAGA) reported a net asset value (NAV) of NOK  322.8 million end of the first quarter 2019, corresponding to NOK 1.21 per outstanding share, excluding minority interests and with Vallhall valued at book value. By the end of the first quarter, Saga had a cash balance of NOK 135 million. All long-term debt are related to the real estate owned by Vallhall (Saga's ownership is 55%). During the quarter, the market value of shares held in SD Standard Drilling Plc and Vistin Pharma ASA increased with NOK 21.6 million. This is classified as

CapMan Buyout exits Komas to Componenta Corporation

CapMan Buyout press release16 May 2019 at 08:00 a.m. EEST CapMan Buyout exits Komas to Componenta Corporation Funds managed by CapMan have signed an agreement on selling the shares and capital loans of Komas Oy, a machining operation company, to Componenta Corporation. Komas is a manufacturer of machined components, forged blanks, hydraulic pipes and plate cuttings. At the end of 2018, the company employed 313 people in Jyväskylä, Härmä, Kurikka, Leppävesi and Sastamala. Key customers of Komas include major international OEMs of machinery and equipment. According to the arrangement,

Componenta Corporation Business Review January-March 2019

Componenta Corporation Stock Exchange Release on 16 May 2019 at 8.00 Decline in delivery volumes in Sweden weakened the operating result.  This is not an interim report as specified in the IAS 34 standard. The company complies with half-yearly reporting according to the Finnish Securities Markets Act and discloses business reviews for the first three and nine-month periods of the year, in which key information regarding the company’s financial situation and development will be presented. The financial information presented in this business review is unaudited. January – March

Panoro Energy (Oslo Ticker: PEN): Invitation to First Quarter 2019 conference call 23 May 2019

Panoro Energy’s Q1 2019 report will be published on Thursday, 23 May 2019 and will be available on our website http://www.panoroenergy.com at 07:30 a.m. CET. Panoro will hold a conference call at 09:00 a.m. CET on Thursday 23 May 2019, during which management will discuss Panoro's 2019 first quarter results. After conclusion of the discussion, participants invited to ask questions on the Q1 report. Participants are requested to dial in five to ten minutes prior to the start time using the numbers and password below: Local - Oslo, Norway +47 21 563 318Toll Free – Norway

Componenta to acquire Komas Oy and become the leading metal component manufacturer in Finland

Componenta Corporation Stock Exchange Release, Insider Information, 16 May 2019 at 8.00 Componenta Corporation (“Componenta”) has signed an agreement on purchasing the shares and capital loans of Komas Oy (“Komas”), a machining operation company, from funds managed by CapMan, Fortaco Oy and certain private persons. Komas is a manufacturer of machined components, forged blanks, hydraulic pipes and plate cuttings. In 2018, Komas had net sales EUR 44.9 million according to Finnish Accounting Standards (FAS) and EBITDA of EUR 2.0 million (FAS). At the end of 2018, the company employed 313

Ten winners at The Educators’ Challenge Awards

The Global Challenges Foundation are hosting The Educators’ Challenge Awards in London on May 15th. The award winners include various kinds of educators who have done an outstanding job of promoting positive action in regard to both global collaboration and global catastrophic risks.“The Educators’ Challenge Awards is part of our mission to explore how to effectively communicate and increase engagement among young people and the general public around global risks such as climate change, biological collapse and weapons of mass destruction,  which all require improved global cooperation,”

NEXT Biometrics and Newland Enter into Partnership Agreement to Deliver Biometric POS

Oslo, May 16, 2019 –NEXT Biometrics (Oslo Bors: NEXT), a global leader in fingerprint sensor technology, announces that it has entered into a supply agreement with Fujian Newland Payment Technology Co., Ltd. (Newland). Newland is the market-leading Point-of-Sale (POS) terminal manufacturer in China and ranks number two in the global POS sector according to The Nilson Report. The agreement provides for the integration of different types of NEXT Biometrics’ high-quality, large-area fingerprint sensors into a range of Newland`s POS terminals for sales on a global scale. The parties have

CLX Communications AB (publ): Invitation to conference call and web presentation of Sinch Q1 2019 interim report

Stockholm, Sweden – CLX Communications AB (publ) – XSTO: SINCH CLX Communications AB will publish its 2019 first quarter interim report on Friday, May 17, 2019, at 07:30 AM CET. You are invited to participate in a conference call at 09:00 AM CET on the same day. Oscar Werner, CEO, and Roshan Saldanha, CFO, will present the report and review the results. Time for publication of the interim reportFriday May 17, 2019, at 07:30 AM CET Time for conference call and web presentationFriday May 17, 2019, at 09:00 AM CET Dial-in numbers and access codePlease make sure you are

YIT construction industry´s most attractive employer for students

YIT Corporation Press release, May 16, 2019, at 7 a.m.Technology students ranked YIT as the most ideal construction industry employer in Universum’s Student Survey. YIT also improved its ranking in the list of ideal technology employers: the company was ranked 5th, which is YIT’s best ranking so far in this list. Every year, YIT offers diverse summer jobs and work placements to about 1,000 young people in the spirit of doing things together. Traditionally, student employees spend the summer at YIT learning the ropes and putting the teachings of their construction studies into practice.

NGEx Reports First Quarter 2019 Results

VANCOUVER, May 15, 2019 /CNW/: NGEx Resources Inc. (TSX: NGQ) (NASDAQ STOCKHOLM: NGQ) (“NGEx” or the “Company”) is pleased to announce its results for the three months ended March 31, 2019. HIGHLIGHTS · On April 17, 2019, the Company announced its intention to spin out its Los Helados Project and exploration portfolio into a wholly-owned subsidiary of NGEx, 11264796 Canada Inc. (“Spinco”) through a Plan of Arrangement under the Canada Business Corporations Act (the “Arrangement”). The Arrangement is designed to deliver greater value to shareholders by unlocking the value of the Los

Cantargia: abstract published for the oral presentation of antibody CAN04 phase I data at ASCO

Cantargia AB today announces that the abstract of the upcoming oral presentation of CAN04 phase I clinical data at the 2019 ASCO Annual Meeting is published on the conference website. The abstract reports available data on the 22 patients in the phase I trial based on the interim analysis performed in February 2019. These data show that the safety profile of CAN04 was good and that CAN04 treatment led to a decrease of the biomarkers IL-6 and CRP already after two weeks of therapy. Nine patients had stable disease as determined by irRC after eight weeks follow up. One patient with pancreatic

Alligator Bioscience: ADC-1013 clinical Phase I data to be presented at ASCO

Lund, Sweden, May 15, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that Janssen Biotech, Inc. (Janssen) will present data from a Phase I clinical study of ADC-1013 (JNJ-7107) at the upcoming ASCO Annual meeting held in Chicago on May 31- June 4. The study results show that side effects were generally mild and transient. The primary aim of the study was safety and to establish a recommended dose for Phase II. The study is still ongoing and has enrolled a total of 95 patients. The maximum tolerated dose has not yet been reached. Doses up to 1200 μg/kg i.v without

BerGenBio to present new NSCLC and AML clinical data and biomarker data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO 2019

· Two peer reviewed abstracts on Phase II clinical data with bemcentinib accepted for presentation at ASCO 2019 · Non-Small-Cell Lung Cancer (NSCLC) trial of bemcentinib in combination with pembrolizumab, data to be presented includes safety, response rates and overall survival · Acute Myeloid Leukaemia (AML) trial of bemcentinib in combination with low dose AraC chemotherapy or decitabine reported safety and rapid, durable complete response ratesBergen, Norway, 15 May 2019 – BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase

Oncopeptides Announces Melflufen Data Accepted for Presentation at 2019 ASCO Annual Meeting

Stockholm – May 15, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from its Phase 1/2 O-12-M1 study evaluating melflufen, a lipophilic peptide-conjugated alkylator belonging to the novel class of peptidase enhanced cytotoxics, in the treatment of relapsed/refractory multiple myeloma (RRMM) have been selected for poster presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4 in Chicago.The data offers an analysis of time to next treatment (TTNT) in patients with RRMM who were treated with melflufen and

There are no items matching the current filter
There are no more items matching the current filter
Back to top